HONG KONG – Asian drugmakers are increasingly embracing artificial intelligence (AI) technologies for drug discovery. The latest example is Japanese drug developer Ono Pharmaceutical Co. Ltd., which recently entered a partnership with U.S. AI-focused biotech firm Twoxar Inc.